Dominic Reynolds

Dominic Reynolds, Ph.D., serves as the Chief Scientific Officer at Remix, where he spearheads the discovery and development of small molecules aimed at reprogramming RNA processing for therapeutic applications. With over 20 years of experience in the biotechnology sector, Dominic has a proven track record of building successful biotech companies and advancing innovative drug discovery programs.

Dominic began his career at Millennium Pharmaceuticals, where he developed a strong foundation in medicinal chemistry and drug discovery. He joined Forma Therapeutics and then H3 Biomedicine as a launching member, assuming the role of VP, Head of Chemistry, at H3 Biomedicine, where he was critical in driving their drug discovery initiatives. As a drug discovery consultant for Third Rock Ventures and Atlas Venture, Dominic provided strategic guidance to seed-stage biotech companies, leveraging his extensive experience in oncology and neurodegeneration therapeutics. His leadership and scientific expertise have been pivotal in advancing multiple therapeutic candidates into clinical trials and developing sustainable drug discovery pipelines. Dominic earned his Ph.D. in synthetic chemistry from the University of Cambridge and completed postdoctoral training at Harvard University, focusing on natural product synthesis.

At Remix, Dominic’s vision and expertise drive the company’s mission to develop novel RNA-targeted therapeutics. His leadership is characterized by confident communication, building high performing teams, and a commitment to delivering innovative science on aggressive timelines. Dominic is dedicated to further developing Remix’s unique and innovative approach to manipulating RNA and translating that science into meaningful treatments for patients.